(Photo credit: Getty Images/Westend61)
Over the last year, digital has transformed the caregiver experience, but pharma has also been undergoing a metamorphosis in order to reach patients.
During the pandemic, life science companies were pushed to reconfigure their care in order to meet the needs of some of the most at-risk patients.
MobiHealthNews sat down with the leader of pharma giant Otsuka s Global Clinical Development on Nephrology, Dr. Charlotte Jones-Burton, to talk about innovating for rare disease, digital in clinical trials and lessons learned from past tech partnerships.
One of Otsuka s treatment areas focuses on autosomal dominant polycystic kidney disease (ADPKD), a genetic disease that requires substantial monitoring. There have always been challenges for patients living with this disease, which have been exacerbated during the pandemic.